There's a good chance that Incyte (INCY) will miss Wall Street earnings and revenue projections when it reports first quarter results on April 30. That's because Incyte is a biotech adolescent. Think awkward. The company is old enough to have substantial revenue from one drug, Jakafi, an oral JAK (janus kinase) inhibitor. In the short […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
